Skip to content

Study · In vitro (cells) · 1995

2 results

Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor.

Adamou JE, Aiyar N, Van Horn S, Elshourbagy NA

Biochemical and biophysical research communications1 Apr 1995Cited by 62 (Europe PMC)

PMID7733904 (opens in a new tab)DOI10.1006/bbrc.1995.1515 (opens in a new tab)PepBankPUB-07733904
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In COS-7 cells expressing the human VIP-2 receptor, [125I]VIP bound with high affinity (IC50 0.93 nM).

    In plain wordsIn cells carrying the human VIP-2 receptor, VIP bound to the receptor with high affinity.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP binding affinity at the human VIP-2 receptor
    Study

    n: not reported in source

    COS-7 cells expressing the human VIP-2 receptor
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    0.93 nM
    [125I]VIP binding, COS-7 cells with human VIP-2 receptor

    Source sentences

    Summary
    Expression of the human VIP-2 receptor in COS-7 cells confered high affinity binding to [125I] VIP (IC50 = 0.93 nM), which was displaced by unlabeled PACAP-38 (IC50 = 6.2 nM).
    1 context sentence
    Summary · context
    A full-length clone encoding the human VIP-2 receptor was isolated from a human placenta cDNA library.
  2. 02LabIn vitro (cells)Activity measurement

    In COS-7 cells expressing the human VIP-2 receptor, VIP and PACAP-38 were equally potent in stimulating cAMP accumulation.

    In plain wordsIn cells carrying the human VIP-2 receptor, VIP raised cAMP as strongly as PACAP-38.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changecAMP accumulation, VIP versus PACAP-38
    Study

    n: not reported in source

    COS-7 cells expressing the human VIP-2 receptor
    Comparator
    PACAP-38
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    VIP and PACAP-38 were equipotent in stimulating accumulation of cAMP in COS-7 cells transfected with the human VIP-2 receptor.
    1 context sentence
    Summary · context
    A full-length clone encoding the human VIP-2 receptor was isolated from a human placenta cDNA library.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.